The Food and Drug Administration recently approved Sun Pharmaceuticals' metformin hydrochloride tablets to improve glycemic control in adults with Type 2 diabetes.
The drug is intended to help control high blood sugar when paired with diet and exercise.
The tablets are a generic equivalent of Raleigh, N.C.-based Santarus' Glumetza tablets, which post annual sales of about $1.2 billion in the United States.
Mumbai, India-based Sun Pharmaceuticals expects to launch the tablets within the next few weeks.
More articles on the drug market:
FDA grants priority review status to muscular dystrophy drug
FDA seeks to increase access to Naloxone
Online market for illegal drugs skyrockets: 6 things to know